SCHEMBL17870936

SCHEMBL17870936

CCS(=O)(=O)N1C(=O)C[C@H]1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 3/20 0.49
ALDH1A1 P00352 6/20 0.42
KMT2A Q03164 5/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 2/20 0.42
POLB P06746 2/20 0.42
HPGD P15428 1/20 0.42
BRD4 O60885 3/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 1/20 0.40
RECQL P46063 1/20 0.40
TSHR P16473 1/20 0.40
ATM Q13315 1/20 0.40
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19471191 1.00 RIPK1 (0.49) RIPK1ALDH1A1KMT2AKDM4EMEN1
SCHEMBL19471147 0.79 ALDH1A1 (0.42) RIPK1ALDH1A1KMT2ABRD4RAB9A
SCHEMBL17870950 0.79 RIPK1 (0.48) RIPK1ALDH1A1KMT2ABRD4RAB9A
SCHEMBL19471106 0.79 RIPK1 (0.48) RIPK1ALDH1A1KMT2ABRD4RAB9A
SCHEMBL17870960 0.79 ALDH1A1 (0.42) RIPK1ALDH1A1KMT2ABRD4RAB9A
SCHEMBL17870941 0.77 RIPK1 (0.53) RIPK1ALDH1A1KMT2ABRD4RAB9A
SCHEMBL17870940 0.77 RIPK1 (0.53) RIPK1ALDH1A1KMT2ABRD4RAB9A
SCHEMBL30054156 0.77 RIPK1 (0.53) RIPK1ALDH1A1KMT2ABRD4RAB9A
SCHEMBL1827356 0.74 RIPK1 (0.45) RIPK1ALDH1A1KMT2AMEN1BRD4
SCHEMBL19471217 0.71 RIPK1 (0.48) RIPK1ALDH1A1KMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11478438-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2022-10-25 US disclosed
US-11090307-B2 Treating male senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-17 US disclosed
CN-107108492-B Cell necrosis inhibitor 北京生命科学研究所 2021-03-19 CN disclosed
US-20200182617-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-06-11 US disclosed
US-20200182617-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-06-11 US disclosed
US-20200046714-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-13 US disclosed
US-10555920-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-11 US disclosed
US-10555920-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-11 US disclosed
US-20190038578-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2019-02-07 US disclosed
US-20190038578-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2019-02-07 US disclosed
US-10092529-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-10-09 US disclosed
EP-3224245-B1 NECROSIS INHIBITORS NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) 2018-09-12 EP disclosed
US-20170304237-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-26 US disclosed
US-20170304237-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-26 US disclosed
US-20170304237-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-26 US disclosed
EP-3224245-A1 NECROSIS INHIBITORS National Institute Of Biological Sciences, Beijing (CN) 2017-10-04 EP disclosed
WO-2016101887-A1 NECROSIS INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2016-06-30 WO disclosed
WO-2016101887-A1 NECROSIS INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304237-A1 Necrosis Inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885ALDH1A1 3900/4885KMT2A 3654/4885
US-11478438-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885ALDH1A1 4104/4885KMT2A 4194/4885
US-11090307-B2 Treating male senescence RIPK3, RIPK1, MLKL RIPK1 2/4885ALDH1A1 2786/4885KMT2A 2508/4885
US-20200046714-A1 Treating Male Senescence RIPK3, RIPK1, MLKL RIPK1 2/4885ALDH1A1 2786/4885KMT2A 2508/4885
US-20190038578-A1 Necrosis Inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885ALDH1A1 4104/4885KMT2A 4194/4885
US-10092529-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885ALDH1A1 3900/4885KMT2A 3654/4885
US-10555920-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885ALDH1A1 4104/4885KMT2A 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.